From victim to ally: The kidney as an emerging target for the treatment of diabetes mellitus

Current Medical Research and Opinion

Volumn 25, Issue 3, 2009, Pages 671-681

  Bays, Harold ^a  

^a LOUISVILLE METABOLIC AND ATHEROSCLEROSIS RESEARCH CENTER   (United States)

Author keywords

Diabetes mellitus, type 2; Glucose; Renal glucose excretion; SGLT2 inhibitors; Sodium glucose cotransporter

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; 3 (5 BENZOFURANYL) 1 [2 HYDROXY 6 [6 O (METHOXYCARBONYL) BETA DEXTRO GLUCOPYRANOSYL] 4 METHYLPHENYL] 1 PROPANONE; ANTIDIABETIC AGENT; ASP 1941; AVE 2268; BI 10773; BI 44847; DAPAGLIFLOZIN; GLUCOSE; GLUCOSE TRANSPORTER; INSULIN; JNJ 28431754; METFORMIN; PHLORIZIN; R 7201; REMOGLIFLOZIN; SAR 7266; SERGLIFLOZIN; SODIUM GLUCOSE COTRANSPORTER; SODIUM GLUCOSE COTRANSPORTER 1; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 3; SODIUM GLUCOSE COTRANSPORTER 4; SODIUM GLUCOSE COTRANSPORTER 5; SODIUM GLUCOSE COTRANSPORTER 6; SULFONYLUREA DERIVATIVE; TA 7284; TS 033; UNCLASSIFIED DRUG; UNINDEXED DRUG; YM 543;

CHRONIC DISEASE; CLINICAL TRIAL; DOSE RESPONSE; DRUG MECHANISM; DRUG POTENCY; ELECTROLYTE BLOOD LEVEL; ELECTROLYTE URINE LEVEL; FAMILIAL DISEASE; GENETIC DISORDER; GLUCOSE ABSORPTION; GLUCOSE BLOOD LEVEL; GLUCOSE METABOLISM; GLYCEMIC CONTROL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INSULIN RESISTANCE; KIDNEY; KIDNEY PROXIMAL TUBULE; KIDNEY TUBULE ABSORPTION; MEDICAL SOCIETY; MEDLINE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PROTEIN EXPRESSION; RENAL DIABETES; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; URINE VOLUME; VAGINITIS; WEIGHT GAIN;

EID: 67649359913     PISSN: 03007995     EISSN: 14734877     Source Type: Journal    
DOI: 10.1185/03007990802710422     Document Type: Review

References (60)

1. Patel A, MacMahon S, Chalmers J, et al. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med 2008;358:2560-2572 (Pubitemid 351831357)
2. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993; 329:977-986
3. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008;359:1577-1589
4. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000;321:405-412 (Pubitemid 30609442)
5. Klein R. Hyperglycemia and microvascular and macrovascular disease in diabetes. Diabetes Care 1995;18:258-268
6. Ohkubo Y, Kishikawa H, Araki E, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 1995;28:103-117
7. Gerstein HC, Miller ME, Byington RP, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358:2545-2559 (Pubitemid 351831356)
8. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998; 352:837-853
9. Tomas E, Lin YS, Dagher Z, et al. Hyperglycemia and insulin resistance: possible mechanisms. Ann N Y Acad Sci 2002; 967:43-51 (Pubitemid 34721892)
10. Prentki M, Nolan CJ. Islet beta cell failure in type 2 diabetes. J Clin Invest 2006;116:1802-1812 (Pubitemid 44033300)
11. Kaiser N, Leibowitz G, Nesher R. Glucotoxicity and beta-cell failure in type 2 diabetes mellitus. J Pediatr Endocrinol Metab 2003;16:5-22 (Pubitemid 37259087)
12. Hoerger TJ, Segel JE, Gregg EW, et al. Is glycemic control improving in U.S. adults? Diabetes Care 2008;31:81-86
13. Fox KM, Gerber RA, Bolinder B, et al. Prevalence of inadequate glycemic control among patients with type 2 diabetes in the United Kingdom general practice research database: a series of retrospective analyses of data from 1998 through 2002. Clin Ther 2006;28:388-395
14. Kosachunhanun N, Benjasuratwong Y, Mongkolsomlit S, et al. Thailand diabetes registry project: glycemic control in Thai type 2 diabetes and its relation to hypoglycemic agent usage. J Med Assoc Thai 2006;89(Suppl 1):S66-71 (Pubitemid 44903903)
15. Suh DC, Kim CM, Choi IS, et al. Comorbid conditions and glycemic control in elderly patients with type 2 diabetes mellitus, 1988 to 1994 to 1999 to 2004. J Am Geriatr Soc 2008;56:484-492
16. Grant RW, Cagliero E, Dubey AK, et al. Clinical inertia in the management of type 2 diabetes metabolic risk factors. Diabet Med 2004;21:150-155 (Pubitemid 38221814)
17. Grant R, Adams AS, Trinacty CM, et al. Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care 2007;30: 807-812 (Pubitemid 46556571)
18. Duckworth W. Glycemic control and cardiovascular outcomes - the VA Diabetes Trial. (Abstract) 68th Annual Meeting of the American Diabetes Association, June 6-10, 2008; San Francisco, CA
19. Bays HE. 'Sick fat," metabolic disease, and atherosclerosis. Am J Med 2009;122(Suppl 1):S26-S37
20. Meyer C, Stumvoll M, Nadkarni V, et al. Abnormal renal and hepatic glucose metabolism in type 2 diabetes mellitus. J Clin Invest 1998;102:619-624 (Pubitemid 28376164)
21. Gerich JE, Meyer C, Woerle HJ, et al. Renal gluconeogenesis: its importance in human glucose homeostasis. Diabetes Care 2001; 24:382-391 (Pubitemid 32119142)
22. Meyer C, Dostou JM, Welle SL, et al. Role of human liver, kidney, and skeletal muscle in postprandial glucose homeostasis. Am J Physiol Endocrinol Metab 2002;282:E419-27 (Pubitemid 34654813)
23. Wright EM. Renal Na(+)-glucose cotransporters. Am J Physiol Renal Physiol 2001;280:F10-18
24. Wood IS, Trayhurn P. Glucose transporters (GLUT and SGLT): expanded families of sugar transport proteins. Br J Nutr 2003;89:3-9 (Pubitemid 36187532)
25. Wright EM, Hirayama BA, Loo DF. Active sugar transport in health and disease. J Intern Med 2007;261:32-43 (Pubitemid 46046470)
26. Wright EM, Turk E. The sodium/glucose cotransport family SLC5. Pflugers Arch 2004;447:510-518 (Pubitemid 38241437)
27. Brown GK. Glucose transporters: structure, function and consequences of deficiency. J Inherit Metab Dis 2000;23:237-46 28. Lee YJ, Han HJ. Regulatory mechanisms of Na(+)/glucose cotransporters in renal proximal tubule cells. Kidney Int Suppl 2007;106:S27-35 (Pubitemid 30330406)
28. Hediger MA, Rhoads DB. Molecular physiology of sodium-lucose cotransporters. Physiol Rev 1994;74:993-1026
29. Moe OW, Wright SH, Palacin M. Renal handling of organic solutes. In: Brenner B, ed. Brenner and Rector's The Kidney. 8th edn, Vol 1. Philadelphia, PA: Saunders, 2008
30. Mogensen CE. Maximum tubular reabsorption capacity for glucose and renal hemodynamcis during rapid hypertonic glucose infusion in normal and diabetic subjects. Scand J Clin Lab Invest 1971;28:101-109
31. Rahmoune H, Thompson PW, Ward JM, et al. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes 2005;54:3427-3434 (Pubitemid 43334332)
32. Tazawa S, Yamato T, Fujikura H, et al. SLC5A9/SGLT4, a new Na+-dependent glucose transporter, is an essential transporter for mannose, 1,5-anhydro-D-glucitol, and fructose. Life Sci 2005;76:1039-1050
33. Chen J, Feder J, Neuhaus I, et al. Tissue expression profiling of the sodium-glucose co-transporter (SGLT) family: implication for targeting SGLT2 in type 2 diabetes patients. (Abstract) 68th Annual Meeting of the American Diabetes Association, June 6-10, 2008; San Francisco, CA
34. Ehrenkranz JR, Lewis NG, Kahn CR, et al. Phlorizin: a review. Diabetes Metab Res Rev 2005;21:31-38
35. Scholl-Burgi S, Santer R, Ehrich JH. Long-term outcome of renal glucosuria type 0: the original patient and his natural history. Nephrol Dial Transplant 2004;19:2394-2396 (Pubitemid 39214139)
36. Santer R, Kinner M, Lassen CL, et al. Molecular analysis of the SGLT2 gene in patients with renal glucosuria. J Am Soc Nephrol 2003;14:2873-2882 (Pubitemid 37305650)
37. Rossetti L, Smith D, Shulman GI, et al. Correction of hyperglycemia with phlorizin normalizes tissue sensitivity to insulin in diabetic rats. J Clin Invest 1987;79:1510-1515 (Pubitemid 17099657)
38. Blondel O, Bailbe D, Portha B. Insulin resistance in rats with non-insulin-dependent diabetes induced by neonatal (5 days) streptozotocin: evidence for reversal following phlorizin treatment. Metabolism 1990;39:787-793 (Pubitemid 20250989)
39. Kahn BB, Shulman GI, DeFronzo RA, et al. Normalization of blood glucose in diabetic rats with phlorizin treatment reverses insulin-resistant glucose transport in adipose cells without restoring glucose transporter gene expression. J Clin Invest 1991;87:561-570
40. Kim YW, Kim JY, Lee SK. Effects of phlorizin and acipimox on insulin resistance in STZ-diabetic rats. J Korean Med Sci 1995;10:24-30
41. Simonson GD, Kendall DM. Diagnosis of insulin resistance and associated syndromes: the spectrum from the metabolic syndrome to type 2 diabetes mellitus. Coron Artery Dis 2005; 16:465-472 (Pubitemid 44365932)
42. Reaven GM. Insulin resistance, the insulin resistance syndrome, and cardiovascular disease. Panminerva Med 2005;47:201-210
43. Wright EM. I. Glucose galactose malabsorption. Am J Physiol 1998;275(5 Pt 1):G879-82 (Pubitemid 28538938)
44. Booth AN, Jones FT, Deeds F. Metabolic and glucosuria studies on naringin and phloridzin. J Biol Chem 1958;233:280-282
45. De Jonge PC, WieringaT, Van Putten JP, et al. Phloretin - an uncoupler and an inhibitor of mitochondrial oxidative phosphorylation. Biochim Biophys Acta 1983;722:219-225 (Pubitemid 13165729)
46. Tsujihara K, Hongu M, Saito K, et al. Na(+)-glucose cotransporter inhibitors as antidiabetics. I. Synthesis and pharmacological properties of 4'-dehydroxyphlorizin derivatives based on a new concept. Chem Pharm Bull (Tokyo) 1996;44:1174-1180
47. Oku A, Ueta K, Arakawa K, et al. T-1095, an inhibitor of renal Na+-glucose cotransporters, may provide a novel approach to treating diabetes. Diabetes 1999;48:1794-1800 (Pubitemid 29415199)
48. Isaji M. Sodium-glucose cotransporter inhibitors for diabetes. Curr Opin Investig Drugs 2007;8:285-292 (Pubitemid 46557988)
49. Meng W, Ellsworth BA, Nirschl AA, et al. Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. J Med Chem 2008;51:1145-1149
50. Glombik H, Frick W, Heuer H, et al. Synthesis and therapeutic evaluation of thiophene glycosides for the use in treatment of diabetes or for lowering blood sugar levels. Chem Abstr 2004;140 (PCT Int Appl. WO2004007517)
51. Washburn W, Sher P, Wu G. Preparation of O-aryl glucosides as antidiabetic agents and SGLT2 inhibitors. Chem Abstr 2001; 135 (U.S. Patent 6683056)
52. Washburn W. Preparation of O-pyrazole glucoside SGLT2 inhibitors as antidiabetic agents. Chem Abstr 2003;138 (PCT Int. Appl. WO/2003/020737.)
53. Hussey E, Clark R, Amin DM, et al. Early clinical studies to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of single doses of sergliflozin, a novel inhibitor of renal glucose reabsorption, in healthy volunteers and subjects with type 2 diabetes mellitus. (Abstract 189-OR) 67th Annual Meeting of the American Diabetes Association, June 22-26, 2007; Chicago, IL
54. Komoroski B, Vachharajani N, Feng Y, et al. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009 Jan 7. [Epub ahead of print]
55. Leslie B, Tang W, List J. Renal effects of the sodium-glucose cotransporter 2 (SGLT2) inhibitor dapagliflozin (BMS-512148) in patients with type 2 diabetes mellitus (T2DM). American Society of Nephrology Renal Week, November 2008
56. Ahren B. Type 2 diabetes, insulin secretion and beta-cell mass. Curr Mol Med 2005;5:275-286 (Pubitemid 40663134)
57. Alvarez Guisasola F, Tofe Povedano S, Krishnarajah G, et al. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. Diabetes Obes Metab 2008;10(Suppl 1):25-32
58. Hermansen K, Mortensen LS. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. Drug Saf 2007;30:1127-1142 (Pubitemid 350172854)
59. Goudswaard AN, Furlong NJ, Rutten GE, et al. Insulin monotherapy versus combinations of insulin with oral hypoglycaemic agents in patients with type 2 diabetes mellitus. Cochrane Database Syst Rev 2004:CD003418
60. Nesto RW, Bell D, Bonow RO, et al. Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association. Diabetes Care 2004;27:256-263 (Pubitemid 38196741)